Ptbwq6rstlktxbsyeswy imab

Imabiotech Corp

Cambridge, MA, US

Localized in USA, Europe and Asia, ImaBiotech is a Contract Research Organization (CRO) company which supports pharmaceutical compagnies with innovative services from preclinical to clinical stages. ImaBiotech is specialized in a new technology called Mass Spectrometry Imaging which improves Target Engagement, Pharmacokinetics, pharmacodynamics and support of toxicology studies.

Founded by a team of experts in Mass Spectrometry and MALDI Imaging Mass Spectrometry (MALDI imaging), ImaBiotech offers services and software in the healthcare field in order to accelerate the launch of medications on the market, and to strengthen the precision and applications for new medical diagnostic tools.

Recent Publications

  • Hamm G, Bonnel D, Legouffe R, Pamelard F, Delbos J-M, Bouzom Fo, Stauber J. 2012. Quantitative mass spectrometry imaging of propranolol and olanzapine using tissue extinction calculation as... Show more »

Localized in USA, Europe and Asia, ImaBiotech is a Contract Research Organization (CRO) company which supports pharmaceutical compagnies with innovative services from preclinical to clinical stages. ImaBiotech is specialized in a new technology called Mass Spectrometry Imaging which improves Target Engagement, Pharmacokinetics, pharmacodynamics and support of toxicology studies.

Founded by a team of experts in Mass Spectrometry and MALDI Imaging Mass Spectrometry (MALDI imaging), ImaBiotech offers services and software in the healthcare field in order to accelerate the launch of medications on the market, and to strengthen the precision and applications for new medical diagnostic tools.

Recent Publications

  • Hamm G, Bonnel D, Legouffe R, Pamelard F, Delbos J-M, Bouzom Fo, Stauber J. 2012. Quantitative mass spectrometry imaging of propranolol and olanzapine using tissue extinction calculation as normalization factor. Journal of Proteomics 75:4952–4961.
  • Kreye F, Hamm G, Karrout Y, Legouffe R, Bonnel D, Siepmann F, Siepmann J. 2012. MALDI-TOF MS imaging of controlled release implants. Journal of Controlled Release 161:98-108.
  • Ait-Belkacem R, Calligaris D, Sellami L, Villard C, Granjeaud S, Schembri Trs, Berenguer C, Ouafik LH, Figarella-Branger D, Chinot O, Lafitte D. 2013. Tubulin isoforms identified in the brain by MALDI in-source decay.
  • Bonnel D, Franck J, Mériaux Cl, Salzet M, Fournier I. 2013. Ionic matrices pre-spotted MALDI plates for patients markers following, drugs titration and MALDI MSI. Analytical Biochemistry.
  • Navis AC, Niclou SP, Fack F, Stieber D, van Lith S, Verrijp K, Wright A, Stauber J, Tops B, Otte-Holler I, Wevers RA, van Rooij A, Pusch S, von Deimling A, Tigchelaar W, van Noorden CJ, Wesseling P, Leenders WP. 2013. Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: in situ detection of 2-HG and alpha-KG. Acta Neuropathol Commun 1:18.
  • Stauber J. 2013. Quantitation by MS imaging: needs and challenges in pharmaceuticals. Bioanalysis 4:2095-2098.
  • Ait-Belkacem R, Berenguer C, Villard C, Ouafik L, Figarella-Branger D, Beck A, Chinot O, Lafitte D. 2014. Monitoring therapeutic monoclonal antibodies in brain tumor. MAbs 6:1385-1393.
  • Ait-Belkacem R, Berenguer C, Villard C, Ouafik L, Figarella-Branger D, Chinot O, Lafitte D. 2014. MALDI imaging and in-source decay for top-down characterization of glioblastoma. Proteomics 14:1290-1301.
  • Ait-Belkacem R, Dilillo M, Pellegrini D, Yadav A, de Graaf EL, McDonnell LA. 2016. In-Source Decay and Pseudo-MS3 of Peptide and Protein Ions Using Liquid AP-MALDI. J Am Soc Mass Spectrom 27:2075-2079.
  • Satoshi Miyamoto, Cheng-Chih Hsue, Gregory Ham, Manjula Darshia, Maggie Diamond-Stanica, Anne-Emilie Declèves, Larkin Slatera, Subramaniam Pennathur, Jonathan Stauber, Pieter C. Dorresteina, Kumar Sharmaa. 2016. Mass Spectrometry Imaging Reveals Elevated Glomerular ATP/AMP in Diabetes/obesity and Identifies Sphingomyelin as a Possible Mediator. EBioMedicine 7:121-34.
« Show less

Imabiotech Corp has not listed any services.

Clinical Biomarkers
Price on request
Request a quote for more information about this service.
Biomarker Analysis
Price on request
Request a quote for more information about this service.
MALDI Tissue Imaging
Matrix-Assisted Laser Desorption Ionization Tissue Imaging
Price on request

Imabiotech offers a fast solution to assess the target engagement of your drugs using a label free Quantitative MALDI imaging technology.

With this new services, you can screen and select drug candidates based on the co-distribution of drugs with the targets.

Target Engagement Studies

Imabiotech offers a fast solution to assess the target engagement of your drugs using a label free Quantitative MALDI imaging technology.

With this new services, you can screen and select drug candidates based on the co-distribution of drugs with the targets.

Target Engagement Studies

  • Focused drug co-distribution with Targets (Receptor, protein, ligand) using MALDI Imaging Mass Spectrometry and other imaging techniques (IHC, H&E, PET or MRI imaging) in whole body or selected organs
  • Quantitative study of drug, metabolites and biomakers
  • Use of unique dedicated software (quantinetix)
  • High resolution: 20µm

Tissues samples

  • Every organs
  • Snap frozen tissues
  • FFPE tissues

Combined with

  • ImmunoHistoChemistry
  • Hematoxylin & Eosin staining
  • MRI or PET imaging
« Show less
Biomarker Discovery
Price on request

Biomarker are the key components for the evaluation of a disease or disease progression.

In order to satisfy efficacy or toxicity investigation, Imabiotech offers new approach of imaging to localize biomarkers of efficacy or toxicity in many different options:

  • Disease state evaluation
  • Disease progression
  • Read-out or... Show more »

Biomarker are the key components for the evaluation of a disease or disease progression.

In order to satisfy efficacy or toxicity investigation, Imabiotech offers new approach of imaging to localize biomarkers of efficacy or toxicity in many different options:

  • Disease state evaluation
  • Disease progression
  • Read-out or companion biomarker for efficacy evaluation
  • Biomarker of drug toxicity

In a single experiment, ImaBiotech evaluates drug distribution with biomarkers using Multimaging platform which combines different imaging techniques to discover and colocalize drugs and biomarkers together.

« Show less
Toxicology
Price on request

Histology shows consequences of toxicology pathology, while ImaBiotech identifies the cause with molecular histology.

Imaging services support your toxicity studies by identifying the specific compound distributions correlated to toxicity effects with Quantitative MALDI Imaging Mass Spectrometry, H&E staining and biomarker... Show more »

Histology shows consequences of toxicology pathology, while ImaBiotech identifies the cause with molecular histology.

Imaging services support your toxicity studies by identifying the specific compound distributions correlated to toxicity effects with Quantitative MALDI Imaging Mass Spectrometry, H&E staining and biomarker imaging techniques.

High Definition Toxicity Studies

  • Focused drug and metabolites distribution with MALDI Imaging Mass Spectrometry
  • Metabolite identification with High Resolution MALDI Imaging Mass Spectrometry
  • Quantitative study combined with staining
  • Use of unique dedicated software (quantinetix)
  • High resolution: 20µm

Tissues sample

  • Every organs
  • Snap frozen tissues
  • FFPE tissues

Combined with

  • ImmunoHistoChemistry
  • Hematoxylin & Eosin staining
« Show less
In vitro PK/PD Models
In vitro pharmacokinetics/pharmacodynamics
Price on request

In just a few days, ImaBiotech provides quantitative distributions of your lead compounds.

To select better drug candidate within a month, Imabiotech offers a combination of pharmacokinetics and pharmacodynamics studies using Quantitative MALDI imaging technology and its proprietary biomarkers databank.

This innovation in... Show more »

In just a few days, ImaBiotech provides quantitative distributions of your lead compounds.

To select better drug candidate within a month, Imabiotech offers a combination of pharmacokinetics and pharmacodynamics studies using Quantitative MALDI imaging technology and its proprietary biomarkers databank.

This innovation in drug development process allows the distribution study of drug and metabolites with their read-out molecules. This provides a very fast evaluation drug candidate efficacy or toxicity.

With this new services, you can screen and select the best drug candidates based on the global distribution of drugs and metabolites with the level of biomarker changes.

Pharmacokinetics/dynamics Studies

  • Quantification and distribution of drugs and metabolites
  • Focused biomarker and drug co-distribution with MALDI Imaging Mass Spectrometry and other imaging techniques (IHC, H&E, PET or MRI imaging) in whole body or cellular levels
  • Endogenous Metabolite identification with High Resolution MALDI Imaging Mass Spectrometry
  • Quantitative study of drug, metabolites and biomakers
  • Use of unique dedicated software (quantinetix)
  • High resolution: 20µm

Tissues sample

  • Every organs
  • Snap frozen tissues
  • FFPE tissues

Combined with

  • ImmunoHistoChemistry
  • Hematoxylin & Eosin staining
  • MRI or PET imaging
« Show less
In vivo ADME Studies
Price on request

Study Drug distribution at early stage to select best drug candidates : Screen your molecules, Faster, Better and Cheaper.

ImaBiotech developed a new way to screen your molecules. MALDI Imaging Mass Spectrometry technologies are perfectly suitable for drug candidates screening. Indeed quick study initiation allows obtaining the... Show more »

Study Drug distribution at early stage to select best drug candidates : Screen your molecules, Faster, Better and Cheaper.

ImaBiotech developed a new way to screen your molecules. MALDI Imaging Mass Spectrometry technologies are perfectly suitable for drug candidates screening. Indeed quick study initiation allows obtaining the distribution comparison of different drug candidates at different time points per organ (whole-body section) or per histological region (single organ). This precious information allows to quickly identify or/and optimize a drug candidate.

Screening Studies

  • 2 weeks - 20 drugs and metabolites distribution
  • Organs or Whole body distributions
  • Faster than classical methods

Tissues samples

  • Necropsy
  • Biopsy
  • Whole body
« Show less
Ask A Question Find what you're looking for? If not, you can ask this lab a question:

Imabiotech Corp has not received any ratings.

Be the first to endorse Imabiotech Corp

Endorse this lab